Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer

Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses updated safety findings from the phase 1b/2 ELEVATE umbrella trial (NCT05563220) investigating elacestrant (Orserdu)–based combination regimens in patients with estrogen receptor (ER)–positive, HER2-negative, locally advanced or metastatic breast cancer.